<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ganciclovir (systemic): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ganciclovir (systemic): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Ganciclovir (systemic): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11692" href="/d/html/11692.html" rel="external">see "Ganciclovir (systemic): Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="15994" href="/d/html/15994.html" rel="external">see "Ganciclovir (systemic): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F8106920"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Hematologic toxicity:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Granulocytopenia, anemia, thrombocytopenia, and pancytopenia have been reported with ganciclovir.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Impairment of fertility:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Based on animal data and limited human data, ganciclovir may cause temporary or permanent inhibition of spermatogenesis in males and suppression of fertility in females.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Fetal toxicity:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Based on animal data, ganciclovir has the potential to cause birth defects in humans.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Mutagenesis and carcinogenesis:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Based on animal data, ganciclovir has the potential to cause cancer in humans.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F8106925"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Cytovene [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52869176"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Cytovene</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F8106930"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antiviral Agent</li></ul></div>
<div class="block doa drugH1Div" id="F8107009"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Ganciclovir is not recommended in patients with an ANC &lt;500 cells/mm<sup>3</sup>, hemoglobin &lt;8 g/dL, or platelet count &lt;25,000 cells/mm<sup>3</sup>; colony stimulating factors have been shown to increase neutrophil and white blood cell counts in patients receiving ganciclovir.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="69725f51-5e30-4d1c-8231-1a734cb7121c">Cytomegalovirus, preemptive therapy in hematopoietic cell transplant recipients</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cytomegalovirus, preemptive therapy in hematopoietic cell transplant recipients (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>&lt;100 days post-transplant:</i>
<b>IV: </b>5 mg/kg/dose every 12 hours for 7 days (autologous transplant) or 7 to 14 days (allogenic transplant), then 5 mg/kg/dose every 24 hours for 1 to 2 weeks or until the indicator test is negative (minimum total induction and maintenance treatment is 2 weeks when 14 days of twice daily is used and 3 weeks when a 7-day induction course is used) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19747629']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19747629'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>&gt;100 days post-transplant:</i>
<b>IV: </b>5 mg/kg/dose every 12 hours for 7 to 14 days, then 5 mg/kg/dose every 24 hours for 1 to 2 weeks or until the indicator test is negative (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19747629']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19747629'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5ea6a7a6-db7e-4637-979f-2a70ad6b4548">Cytomegalovirus, prophylaxis in transplant recipients</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cytomegalovirus, prophylaxis in transplant recipients:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Allogeneic hematopoietic cell transplant recipients: <b>IV:</b> 5 mg/kg/dose every 12 hours for 5 to 7 days, then 5 mg/kg/dose every 24 hours until day 100 post-transplant (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19747629']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19747629'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Solid organ transplant recipients: <b>IV:</b> 5 mg/kg/dose every 24 hours; duration of prophylaxis is dependent on type of transplant, as well as donor and recipient cytomegalovirus (CMV) serostatus (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30817026','lexi-content-ref-23896556']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30817026','lexi-content-ref-23896556'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7470c9b2-9ea3-469c-bccb-a8ef3f8cad3f">Cytomegalovirus, treatment, other tissue-invasive disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cytomegalovirus, treatment, other tissue-invasive disease (eg, colitis, esophagitis, pneumonitis, neurological disease) (off-label use):</b>
<b>IV: </b>5 mg/kg/dose every 12 hours; duration varies based on site and severity of infection, type of immunocompromise, and clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17640310','lexi-content-ref-30817026','lexi-content-ref-HHS.2','lexi-content-ref-23896556']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17640310','lexi-content-ref-30817026','lexi-content-ref-HHS.2','lexi-content-ref-23896556'])">Ref</a></span>). For neurological disease, use in combination with foscarnet until symptoms improve (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e0ca0100-6a3b-421c-93dc-fc040832500b">Cytomegalovirus, treatment, resistant virus</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cytomegalovirus, treatment, resistant virus (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>UL97 mutation for &lt;5x ganciclovir EC50:</i>
<b>IV: </b>10 mg/kg/dose every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30817026','lexi-content-ref-23896556']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30817026','lexi-content-ref-23896556'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Ganciclovir-resistant strains: </i>
<b>IV: </b>5 mg/kg/dose every 24 hours in combination with daily foscarnet and monthly CMV hyperimmunoglobulin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11981729']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11981729'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0dc7876b-bafe-46e9-b2a8-fca20d20c0df">Cytomegalovirus retinitis, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cytomegalovirus retinitis, treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Initial therapy for immediate sight-threatening lesions (adjacent to the optic nerve or fovea):</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Intravitreal injection (off-label route):</b> 2 mg in 0.05 mL of an extemporaneously prepared solution administered as an intravitreal injection once weekly until lesion inactivity is achieved; administer in combination with a systemic antiviral (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33542372','lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33542372','lexi-content-ref-HHS.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 5 mg/kg/dose every 12 hours for 14 to 21 days; for patients with HIV and high-risk solid organ transplant recipients, follow with chronic maintenance therapy (secondary prophylaxis) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30817026','lexi-content-ref-HHS.2','lexi-content-ref-23896556']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30817026','lexi-content-ref-HHS.2','lexi-content-ref-23896556'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Chronic maintenance therapy (secondary prophylaxis) (alternative agent):</i>
<b>IV:</b> 5 mg/kg/dose once daily (7 days/week) <b>or</b> 6 mg/kg/dose once daily (5 days/week). For patients with HIV, continue ≥3 to 6 months until sustained CD4 count &gt;100 cells/mm<sup>3</sup> in response to antiretroviral therapy; discontinue only after consultation with an ophthalmologist (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="dd7a0adc-e37a-48a8-98cc-4b363dab1298">Varicella zoster virus</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Varicella zoster virus (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Acute retinal necrosis (adjunctive agent): Intravitreal injection (off-label route):</b> 2 mg in 0.05 mL of an extemporaneously prepared solution administered as an intravitreal injection twice weekly until there is evidence of clinical response; administer in combination with systemic antiviral therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Progressive outer retinal necrosis:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Intravitreal injection (off-label route):</b> 2 mg in 0.05 mL of an extemporaneously prepared solution administered as an intravitreal injection twice weekly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22801826','lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22801826','lexi-content-ref-HHS.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 5 mg/kg/dose every 12 hours <b>plus</b> intravitreal ganciclovir and/or intravitreal foscarnet (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Duration:</b> Not well defined; based on clinical, virologic, and immunologic responses in consultation with an ophthalmologist (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990524"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function: IV:</b></p>
<table border="1" frame="border" rules="all" style="margin-left:2em;">
<caption>
<b>Ganciclovir Dose Adjustments for Altered Kidney Function<sup>a,b,c</sup></b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;">CrCl (mL/minute)</p></th>
<th align="center">
<p style="text-indent:0em;">Induction</p>
<p style="text-indent:0em;">
<b>If the usual recommended dose is 5 mg/kg/dose every 12 hours </b></p></th>
<th align="center">
<p style="text-indent:0em;">Maintenance</p>
<p style="text-indent:0em;">
<b>If the usual recommended dose is 5 mg/kg/dose every 24 hours</b></p></th></tr></thead>
<tfoot>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>a</sup> Manufacturer's labeling</p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>b</sup> Calculated using the Cockcroft-Gault equation</p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>c</sup> Optimal ganciclovir pharmacokinetic/pharmacodynamic targets and dose adjustments in kidney dysfunction are not well established. A pharmacokinetic study with Monte Carlo simulations in critically ill patients with kidney impairment suggests using higher than manufacturer-recommended ganciclovir doses to attain minimum ganciclovir target trough concentrations of &gt;1.5 mg/L (the median 50% inhibitory concentration in ganciclovir-sensitive cytomegalovirus isolates) in patients with CKD-EPI estimated GFR &lt;50 mL/minute/1.73 m<sup>2</sup> (Krens 2020). However, the risks and benefits of utilizing higher doses have not been evaluated; individualized therapy along with therapeutic drug monitoring are likely needed in these patients (Ho 2021).</p></td></tr></tfoot>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">≥70 mL/minute</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">No dosage adjustment necessary</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">No dosage adjustment necessary</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">50 to &lt;70 mL/minute</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2.5 mg/kg/dose every 12 hours</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2.5 mg/kg/dose every 24 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">25 to &lt;50 mL/minute</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2.5 mg/kg/dose every 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1.25 mg/kg/dose every 24 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 to &lt;25 mL/minute</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1.25 mg/kg/dose every 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.625 mg/kg/dose every 24 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">&lt;10 mL/minute</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1.25 mg/kg/dose 3 times weekly (every 48 to 72 hours)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.625 mg/kg/dose 3 times weekly (every 48 to 72 hours)</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Dialyzable (50% to 60% using low-flux filters (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2854457','lexi-content-ref-1846060']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2854457','lexi-content-ref-1846060'])">Ref</a></span>)):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note</b>: Recommended dose adjustments are based on a usual induction dose of 5 mg/kg/dose every 12 hours and a maintenance dose of 5 mg/kg/dose every 24 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Induction: 1.25 mg/kg/dose 3 times weekly (after hemodialysis on dialysis days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19397464']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19397464'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Maintenance: 0.625 mg/kg/dose 3 times weekly (after hemodialysis on dialysis days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19397464']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19397464'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note</b>: Recommended dose adjustments are based on an induction dose of 5 mg/kg/dose every 12 hours and a maintenance dose of 5 mg/kg/dose every 24 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Induction: 1.25 mg/kg/dose 3 times weekly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Maintenance: 0.625 mg/kg/dose 3 times weekly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Recommendations are based on high-flux dialyzers and effluent flow rates of 20 to 25 mL/kg/hour (or ~1,500 to 3,000 mL/hour) unless otherwise noted. Appropriate dosing requires consideration of adequate drug concentrations (eg, site of infection) and consideration of initial loading doses. Close monitoring of response and adverse reactions (eg, hematologic toxicity) due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Recommended dose adjustments assume minimal kidney function and are based on a usual induction dose of 5 mg/kg/dose every 12 hours and a maintenance dose of 5 mg/kg/dose every 24 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV</b>:</p>
<p style="text-indent:-2em;margin-left:6em;">Induction: 2.5 mg/kg/dose every 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24145543','lexi-content-ref-32547394','lexi-content-ref-21075610','lexi-content-ref-24853257']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24145543','lexi-content-ref-32547394','lexi-content-ref-21075610','lexi-content-ref-24853257'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Maintenance: 1.25 mg/kg/dose every 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24145543','lexi-content-ref-32547394','lexi-content-ref-21075610','lexi-content-ref-24853257']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24145543','lexi-content-ref-32547394','lexi-content-ref-21075610','lexi-content-ref-24853257'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Appropriate dosing requires consideration of adequate drug concentrations (eg, site of infection) and consideration of initial loading doses. Close monitoring of response and adverse reactions (eg, hematologic toxicity) due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Recommended dose adjustments assume minimal kidney function and are based on a usual induction dose of 5 mg/kg/dose every 12 hours and a maintenance dose of 5 mg/kg/dose every 24 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Induction: 2.5 mg/kg/dose every 24 hours (when scheduled dose falls on a PIRRT day, administer after PIRRT) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Maintenance: 1.25 mg/kg/dose every 24 hours (when scheduled dose falls on a PIRRT day, administer after PIRRT) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50987831"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doo drugH1Div" id="F56887084"><span class="drugH1">Dosing: Obesity: Adult</span>
<p style="text-indent:0em;display:inline">The recommendations for dosing in patients with obesity are based upon the best available evidence and clinical expertise. Senior Editorial Team: Jeffrey F. Barletta, PharmD, FCCM; Manjunath P. Pai, PharmD, FCP; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Class 1, 2, and 3 Obesity (BMI </b>
<b>≥30 kg/m<sup>2</sup>):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> Use <b>ideal body weight</b> for weight-based dosing to avoid overdosing and subsequent toxicity (eg, hematological toxicity) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOO']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOO'])">Ref</a></span>). Consider the use of therapeutic drug monitoring (if available) to minimize drug toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26824942','lexi-content-ref-Expert.DOO']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26824942','lexi-content-ref-Expert.DOO'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Rationale for recommendations: </b>There are no ganciclovir pharmacokinetic or dosing studies in patients with obesity. Available data from patients without obesity, which include wide patient weight ranges, do not statistically support weight to be an important descriptor for IV ganciclovir pharmacokinetics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19738014','lexi-content-ref-31425489']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19738014','lexi-content-ref-31425489'])">Ref</a></span>). This lack of pharmacokinetic data coupled with a profound hematological toxicity profile suggest a conservative approach to use ideal body weight for dose calculations in patients with obesity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOO']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOO'])">Ref</a></span>). Ganciclovir is primarily excreted unchanged in urine and careful attention to estimated kidney function is also essential in patients with obesity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19738014','lexi-content-ref-Expert.DOO']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19738014','lexi-content-ref-Expert.DOO'])">Ref</a></span>).</p></div>
<div class="block doe drugH1Div" id="F8107010"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F8107008"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="15994" href="/d/html/15994.html" rel="external">see "Ganciclovir (systemic): Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Routes of administration may vary (including IV and intravitreal); use caution.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c8a02668-e604-4e85-9089-e88ac178a369">Congenital cytomegalovirus infection, symptomatic; treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Congenital cytomegalovirus (CMV) infection, symptomatic; treatment (continuation from neonatal period):</b> Limited data available: Infants: IV: 6 mg/kg/dose every 12 hours; transition to oral valganciclovir (when able) to complete total treatment duration of 6 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1','lexi-content-ref-25738669','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1','lexi-content-ref-25738669','lexi-content-ref-AAP.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8b6b4406-0b46-47e9-aaac-1e5ae69f7c00">Cytomegalovirus disease, treatment; immunocompromised host</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cytomegalovirus disease, treatment; immunocompromised host:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Non-HIV-exposed/-infected</i>: Infants, Children, and Adolescents: Limited data available:</p>
<p style="text-indent:-2em;margin-left:6em;">Induction therapy (initial treatment): IV: 5 mg/kg/dose every 12 hours for ≥2 to 3 weeks and until resolution of viremia and symptoms. Dose may be increased to 7.5 mg/kg/dose twice daily if response inadequate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30817026','lexi-content-ref-Bradley.1','lexi-content-ref-29596116']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30817026','lexi-content-ref-Bradley.1','lexi-content-ref-29596116'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Chronic maintenance therapy (secondary prophylaxis), if indicated: IV: 5 mg/kg/dose as a single daily dose 5 to 7 days/week; duration dependent on degree of immunosuppression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1'])">Ref</a></span>). <b>Note: </b>Not routinely recommended in solid organ transplant (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30817026','lexi-content-ref-29596116']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30817026','lexi-content-ref-29596116'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>HIV-exposed/-infected </i>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.3'])">Ref</a></span>)<i>: </i>Infants and Children: Limited data available:</p>
<p style="text-indent:-2em;margin-left:6em;">Induction therapy (initial treatment): IV: 5 mg/kg/dose every 12 hours for 14 to 21 days followed by chronic maintenance therapy; may be increased to 7.5 mg/kg/dose twice daily if response inadequate.</p>
<p style="text-indent:-2em;margin-left:6em;">Chronic maintenance therapy (secondary prophylaxis): IV: 5 mg/kg/dose as a single daily dose 5 to 7 days per week; continue maintenance therapy (with ganciclovir, valganciclovir, or foscarnet as appropriate) until patient has been receiving antiretroviral therapy for ≥6 months and achieves age-specific CD4 cell count targets for at least 6 months (age &lt;6 years: CD4 percentage ≥15%; age ≥6 years: &gt;100 cells/mm<sup>3</sup>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b3263819-c441-43ce-bf47-f759cb7d1309">Cytomegalovirus disease, preemptive therapy; transplant recipients</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cytomegalovirus disease, preemptive therapy; transplant recipients:</b> Limited data available: <b>Note:</b> Requires serial blood monitoring for CMV; therapy is initiated when a CMV positivity threshold is reached (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19747629','lexi-content-ref-30817026','lexi-content-ref-29596116']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19747629','lexi-content-ref-30817026','lexi-content-ref-29596116'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hematopoietic cell transplant recipients:</i> Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">&lt;100 days posttransplant<i>:</i> IV: 5 mg/kg/dose every 12 hours for 7 days (autologous transplant) or 7 to 14 days (allogenic transplant), then 5 mg/kg/dose every 24 hours until the indicator test is negative (minimum total induction and maintenance treatment is 2 weeks when 14 days of twice-daily dosing is used and 3 weeks when a 7-day induction course is used) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19747629']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19747629'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;100 days posttransplant: IV: 5 mg/kg/dose every 12 hours for 7 to 14 days, then 5 mg/kg/dose every 24 hours for 1 to 2 weeks or until the indicator test is negative (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19747629']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19747629'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Solid organ transplant recipients:</i> Infants, Children, and Adolescents: IV: 5 mg/kg/dose every 12 hours; individualize duration based on CMV blood concentrations; some institutions decrease frequency to every 24 hours after 2 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30817026','lexi-content-ref-27755504','lexi-content-ref-21941226','lexi-content-ref-27565955']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30817026','lexi-content-ref-27755504','lexi-content-ref-21941226','lexi-content-ref-27565955'])">Ref</a></span>). <b>Note</b>: Preemptive therapy strategy not recommended for lung transplant recipients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30817026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30817026'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4afa9b39-7409-427a-b91b-8419f5960533">Cytomegalovirus disease, prophylaxis; transplant recipients</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cytomegalovirus disease, prophylaxis; transplant recipients: Note:</b> For patients considered at risk for CMV disease based on donor and recipient CMV serostatus:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hematopoietic cell transplant recipients (allogeneic)</i> Infants, Children, and Adolescents: Limited data available: IV: 5 mg/kg/dose every 12 hours for 5 to 7 days starting at neutrophil engraftment, then 5 mg/kg/dose every 24 hours until day 100 posttransplant (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19747629']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19747629'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Solid organ transplant recipients</i>: Infants, Children, and Adolescents: Limited data available: IV: 5 mg/kg/dose every 24 hours; initiate therapy within 10 days after transplant. Oral valganciclovir typically preferred when appropriate. Total duration of prophylaxis varies depending on organ(s) transplanted, donor and recipient CMV serostatus, and immunosuppressive regimen; typically continued for 3 to 6 months; may be continued for up to 12 months in certain cases (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30817026','lexi-content-ref-29596116']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30817026','lexi-content-ref-29596116'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8b1457a2-f080-4123-852a-e107ea984bf3">Cytomegalovirus infection, central nervous system; treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cytomegalovirus infection, central nervous system; treatment: </b>Limited data available: HIV-exposed/-infected:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.3'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">Induction therapy (initial treatment): IV: 5 mg/kg/dose every 12 hours in combination with foscarnet until symptoms improve; follow with chronic maintenance therapy (secondary prophylaxis).</p>
<p style="text-indent:-2em;margin-left:6em;">Chronic maintenance therapy (secondary prophylaxis): IV: 5 mg/kg/dose once daily; continue maintenance therapy (with ganciclovir, valganciclovir, or foscarnet as appropriate) until patient has been receiving antiretroviral therapy for ≥6 months and achieves CD4 cell count targets for at least 6 months (age &lt;6 years: CD4 percentage ≥15%; age ≥6 years: &gt;100 cells/mm<sup>3</sup>).</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents: 5 mg/kg/dose every 12 hours in combination with foscarnet until symptoms improve; optimal duration not defined (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.5']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.5'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3ff24172-b69a-4487-ae90-3284f774d210">Cytomegalovirus retinitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cytomegalovirus retinitis (immunocompromised patients [including patients with HIV]):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>IV:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.3','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.3','lexi-content-ref-AAP.1'])">Ref</a></span>): Limited data available:</p>
<p style="text-indent:-2em;margin-left:8em;">Induction therapy (initial treatment): IV: 5 mg/kg/dose every 12 hours for 14 to 21 days followed by chronic maintenance therapy (secondary prophylaxis); may be increased to 7.5 mg/kg/dose twice daily if response inadequate.</p>
<p style="text-indent:-2em;margin-left:8em;">Chronic maintenance therapy (secondary prophylaxis): IV: 5 mg/kg/dose as a single daily dose 5 to 7 days per week; for patients with HIV, continue maintenance therapy until patient has been receiving antiretroviral therapy for ≥6 months and achieves CD4 cell count targets for at least 6 months (age &lt;6 years: CD4 percentage ≥15%; age ≥6 years: &gt;100 cells/mm<sup>3</sup>); discontinue only after consultation with an ophthalmologist.</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.5','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.5','lexi-content-ref-AAP.1'])">Ref</a></span>): Limited data available:</p>
<p style="text-indent:-2em;margin-left:8em;">Induction therapy (initial treatment): IV: 5 mg/kg/dose every 12 hours for 14 to 21 days, in combination with intravitreal therapy for immediately sight-threatening lesions, followed by chronic maintenance therapy (secondary prophylaxis).</p>
<p style="text-indent:-2em;margin-left:8em;">Chronic maintenance therapy (secondary prophylaxis): IV: 5 mg/kg/dose once daily; for patients with HIV, continue for ≥3 to 6 months until sustained CD4 count &gt;100 cells/mm<sup>3</sup> in response to antiretroviral therapy; discontinue only after consultant with an ophthalmologist.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Intravitreal: </i>Induction therapy (immediately sight-threatening lesions): Children ≥9 years and Adolescents: Limited data available: 2 mg of an extemporaneously prepared solution administered as an <b>intravitreal injection</b> weekly until lesions are inactive; administer with a concomitant systemically administered agent (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.5','lexi-content-ref-AAP.1','lexi-content-ref-23042013']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.5','lexi-content-ref-AAP.1','lexi-content-ref-23042013'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="578ff131-7e71-4184-a8ec-33e0f92967c9">Varicella-zoster, acute retinal necrosis in patients with HIV</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Varicella-zoster, acute retinal necrosis in patients with HIV:</b> Limited data available: Intravitreal: Adolescents: 2 mg of an extemporaneously prepared solution administered as an <b>intravitreal injection</b> twice weekly for 1 to 2 doses in combination with appropriate IV therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.5']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.5'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1205b001-82b6-4923-b7be-146d26e62b1b">Varicella-zoster, progressive outer retinal necrosis in patients with HIV</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Varicella-zoster, progressive outer retinal necrosis in patients with HIV:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>IV</i>: Infants, Children, and Adolescents: IV: 5 mg/kg/dose every 12 hours as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.5','lexi-content-ref-HHS.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.5','lexi-content-ref-HHS.3'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Intravitreal: </i>Infants, Children, and Adolescents: 2 mg of an extemporaneously prepared solution administered as an <b>intravitreal injection</b> twice weekly; administer in combination with IV therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.5','lexi-content-ref-HHS.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.5','lexi-content-ref-HHS.3'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51112462"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Infants, Children, and Adolescents: There are no pediatric-specific recommendations; based on experience in adult patients, dosage adjustment necessary.</p></div>
<div class="block dohp drugH1Div" id="F51112463"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block adr drugH1Div" id="F8106964"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Hyperhidrosis (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (44%), anorexia (14%), vomiting (13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Thrombocytopenia (6%; ≤50,000/mcL: 8% to 57%; &lt;25,000/mcL: 3% to 32%), leukopenia (41%), neutropenia (ANC &lt;500/mcL: 4% to 25%; 500 to 1,000/mcL: 14% to 29%), anemia (25%; hemoglobin &lt;6.5 g/dL: 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Sepsis (15%), infection (13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Retinal detachment (11%; relationship to ganciclovir not established)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (2% to 50%; ≥2.5 mg/dL: 2% to 20%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (48%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Chills (10%), peripheral neuropathy (9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Catheter sepsis (8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Catheter infection (9%), catheter-site reaction (5%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiac arrhythmia, chest pain, edema, hypertension, hypotension, phlebitis, vasodilation</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Abnormal dreams, abnormality in thinking, agitation, anxiety, confusion, depression, dizziness, drowsiness, fatigue, headache, hypoesthesia, insomnia, malaise, myasthenia, pain, paresthesia, psychosis, seizure</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia, cellulitis, dermatitis, skin rash, urticaria, xeroderma</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Weight loss</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distention, abdominal pain, aphthous stomatitis, constipation, dysgeusia, dyspepsia, dysphagia, eructation, flatulence, gastrointestinal perforation, nausea, oral candidiasis, oral mucosa ulcer, pancreatitis, xerostomia</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Hematuria, urinary frequency, urinary tract infection</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Bone marrow failure</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Abnormal hepatic function tests, increased serum alanine aminotransferase, increased serum aspartate aminotransferase, increased serum alkaline phosphatase</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Candidiasis, influenza</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Inflammation at injection site</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, asthenia, back pain, lower limb cramp, muscle spasm, myalgia, tremor</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Conjunctivitis, eye disease (vitreous disorder), eye pain, macular edema, visual impairment</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Deafness, otalgia, tinnitus</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Decreased creatinine clearance, renal failure syndrome, renal function abnormality</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough, dyspnea, upper respiratory tract infection</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Multiorgan failure</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Acidosis, agranulocytosis, amnesia, anaphylaxis, anosmia, aphasia, arthritis, bronchospasm, cardiac conduction disturbance, cataract, cerebrovascular accident, cholelithiasis, cholestasis, cranial nerve palsy (third), dysesthesia, dysphasia, encephalopathy, exfoliative dermatitis, extrapyramidal reaction, facial nerve paralysis, granulocytopenia, hallucination, hemolytic anemia, hemolytic-uremic syndrome, hepatic failure, hepatitis, hypercalcemia, hypersensitivity reaction, hyponatremia, increased serum triglycerides, infertility, intracranial hypertension, irritability, myelopathy, oculomotor nerve paralysis, pancytopenia, peripheral ischemia, pulmonary fibrosis, renal tubular disease, rhabdomyolysis, SIADH, Stevens-Johnson syndrome, testicular hypotrophy, torsades de pointes, ulcerative bowel lesion, vasculitis, ventricular tachycardia, xerophthalmia</p></div>
<div class="block coi drugH1Div" id="F8106951"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to ganciclovir, valganciclovir, acyclovir, or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F8106952"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hematologic toxicity: Neutropenia usually occurs during the first 1 to 2 weeks of treatment but may occur at any time; cell counts usually begin to recover within 3 to 7 days of treatment discontinuation. Use with caution in patients with pre-existing cytopenias and in patients receiving myelosuppressive drugs or irradiation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal toxicity: Increased serum creatinine levels have been reported in elderly patients and transplant recipients receiving concomitant nephrotoxic medications (eg, cyclosporine, amphotericin B).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; dosage adjustment recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Special populations:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Increased serum creatinine levels have been reported; use with caution and closely monitor serum creatinine.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Administration: Ensure patients are adequately hydrated. Avoid rapid infusion. Phlebitis and/or pain may occur at injection site despite adequate dilution; infuse solution into veins with adequate blood flow.</p></div>
<div class="block foc drugH1Div" id="F8107058"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mg/250 mL (250 mL); 500 mg/10 mL (10 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cytovene: 500 mg (1 ea [DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mg (1 ea)</p></div>
<div class="block geq drugH1Div" id="F8106928"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16322180"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Ganciclovir Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg/250 mL (per mL): $0.24</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Ganciclovir Sodium Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg/10 mL (per mL): $7.20</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Ganciclovir Sodium Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $82.08 - $116.72</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52869177"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cytovene: 500 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mg (1 ea)</p></div>
<div class="block adm drugH1Div" id="F8107021"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> For IV infusion; should not be administered by IM, SUBQ, or rapid or bolus IV injection. Administer by slow IV infusion over at least 1 hour. Too rapid infusion can cause increased toxicity due to excessive plasma levels. Flush line well with NS before and after administration.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intravitreal (off-label route):</b> Administer in appropriate sterile setting by health care professional experienced in administration of intravitreal ophthalmic injections. The dose is 2 mg in a volume ranging from 0.04 to 0.1 mL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33542372','lexi-content-ref-27090644','lexi-content-ref-9709750']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33542372','lexi-content-ref-27090644','lexi-content-ref-9709750'])">Ref</a></span>).</p></div>
<div class="block admp drugH1Div" id="F52614354"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Follow same precautions utilized with antineoplastic agents when preparing and administering ganciclovir.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral:</p>
<p style="text-indent:-2em;margin-left:4em;">IV: Administer by slow IV infusion over at least 1 hour; infusing too rapidly can cause increased toxicity due to excessive plasma levels. Flush line well with NS before and after administration. Do not administer IM or SUBQ; may cause severe tissue irritation due to high pH.</p>
<p style="text-indent:-2em;margin-left:4em;">Intravitreal: Administer in appropriate sterile setting by health care professional experienced in administration of intravitreal ophthalmic injections.</p></div>
<div class="block hazard drugH1Div" id="F49132599"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 2]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (USP-NF 2020). Refer to institution-specific handling policies/procedures.</p></div>
<div class="block use drugH1Div" id="F8106944"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Cytomegalovirus, prophylaxis in transplant recipients:</b> Prevention of cytomegalovirus (CMV) disease in adult transplant recipients at risk for CMV disease.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Cytomegalovirus, treatment, retinitis: </b>Treatment (induction and maintenance [secondary prophylaxis]) of CMV retinitis in adults who are immunocompromised, including patients with HIV.</p></div>
<div class="block off-label drugH1Div" id="F45609639"><span class="drugH1">Use: Off-Label: Adult</span><p>Cytomegalovirus, preemptive therapy in hematopoietic cell transplant recipients; Cytomegalovirus, treatment, other tissue-invasive disease; Cytomegalovirus, treatment, resistant virus; Varicella zoster virus</p></div>
<div class="block mst drugH1Div" id="F8106922"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cytovene may be confused with Cytosar, Cytosar-U</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ganciclovir may be confused with acyclovir </p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299387"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of OAT1/3</p></div>
<div class="block dri drugH1Div" id="F8106969"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Amphotericin B: Ganciclovir-Valganciclovir may enhance the nephrotoxic effect of Amphotericin B. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Agents that Undergo Intracellular Phosphorylation may diminish the therapeutic effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): Ganciclovir-Valganciclovir may enhance the nephrotoxic effect of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Didanosine: Ganciclovir-Valganciclovir may increase the serum concentration of Didanosine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant). Management: Avoid use of fexinidazole with OAT1/3 substrates when possible. If combined, monitor for increased OAT1/3 substrate toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Imipenem: Ganciclovir-Valganciclovir may enhance the adverse/toxic effect of Imipenem. Specifically, the risk of seizures may be increased.  Management: Avoid concomitant use of these agents unless the prospective benefits of therapy outweigh the risks.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Maribavir: May diminish the therapeutic effect of Ganciclovir-Valganciclovir.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mycophenolate: May enhance the adverse/toxic effect of Ganciclovir-Valganciclovir. Specifically, the risk for leukopenia or neutropenia may be increased with this combination. Mycophenolate may increase the serum concentration of Ganciclovir-Valganciclovir.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitisinone: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pretomanid: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probenecid: May increase the serum concentration of Ganciclovir-Valganciclovir.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): Ganciclovir (Systemic) may enhance the nephrotoxic effect of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Taurursodiol: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tenofovir Products: May increase the serum concentration of Ganciclovir-Valganciclovir. Ganciclovir-Valganciclovir may increase the serum concentration of Tenofovir Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teriflunomide: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaborbactam: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zidovudine: Ganciclovir-Valganciclovir may enhance the adverse/toxic effect of Zidovudine. Specifically, hematologic toxicity may be enhanced. <i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49306837"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Patients who may become pregnant should undergo pregnancy testing prior to initiation and use effective contraception during and for at least 30 days after the last dose of ganciclovir.</p>
<p style="text-indent:0em;margin-top:2em;">Male patients should use a barrier contraceptive during and for at least 90 days after ganciclovir therapy. Based on data from valganciclovir studies in renal transplant recipients, ganciclovir may cause temporary or permanent inhibition of spermatogenesis.</p></div>
<div class="block pri drugH1Div" id="F8106947"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Ganciclovir crosses the placenta.</p>
<p style="text-indent:0em;margin-top:2em;">Based on animal data, ganciclovir has the potential to cause birth defects in humans.</p>
<p style="text-indent:0em;margin-top:2em;">Outcome information following use of ganciclovir for cytomegalovirus (CMV) infection during pregnancy following a kidney or liver transplant (Miller 1995; Pescovitz 1999; Puliyanda 2005) or in pregnant patients with HIV (Bergin 2014; Brandy 2002) is limited.</p>
<p style="text-indent:0em;margin-top:2em;">Maternal CMV infection can be asymptomatic and self-limited or symptomatic. CMV infection in immunocompromised patients is associated with significant maternal morbidity and mortality. Congenital CMV infection may also occur; hearing loss, intellectual disability, microcephaly, seizures, and other medical problems have been observed in infants with congenital CMV infection.</p>
<p style="text-indent:0em;margin-top:2em;">Until additional data are available, use of ganciclovir for the treatment of congenital CMV outside of a clinical trial is not currently recommended (SMFM 2016).</p>
<p style="text-indent:0em;margin-top:2em;">The indications for treating maternal CMV retinitis during pregnancy are the same as in patients who are not pregnant with HIV. In general, intravitreous injections for local therapy are preferred for retinal disease to limit systemic exposure during the first trimester when possible. Systemic antiviral therapy should be started after the first trimester. Ganciclovir is not the preferred systemic therapy during pregnancy. Close fetal monitoring is recommended (HHS [OI adult 2022]).</p></div>
<div class="block brc drugH1Div" id="F8106950"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if ganciclovir is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfeeding infant, breastfeeding is not recommended by the manufacturer. The Health and Human Services perinatal HIV guidelines do not recommend breastfeeding for patients in the United States with HIV infection when safer infant feeding options are available (HHS [perinatal] 2021).</p>
<p style="text-indent:-2em;margin-left:2em;">Cytomegalovirus can also be transferred via breast milk; the risk of adverse outcomes if infection occurs is more likely in infants born &lt;32 weeks' gestation and &lt;1,500 g (Osterholm 2020).</p></div>
<div class="block dic drugH1Div" id="F8107020"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Some products may contain sodium.</p></div>
<div class="block mop drugH1Div" id="F8107025"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">CBC with differential at baseline and twice weekly (especially in patients with kidney impairment, history of drug-induced leukopenia, or neutrophil counts &lt;1,000 cells/mm<sup>3</sup> at initiation), serum creatinine at baseline and once weekly (Tice 2004); pregnancy test prior to initiation in patients who may become pregnant; frequent ophthalmological exams in patients with CMV retinitis.</p></div>
<div class="block pha drugH1Div" id="F8106992"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Ganciclovir is phosphorylated by viral and cellular kinases into ganciclovir triphosphate which competitively inhibits the binding of deoxyguanosine triphosphate to DNA polymerase resulting in inhibition of viral DNA synthesis.</p></div>
<div class="block phk drugH1Div" id="F8106994"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: Children 9 months to 12 years: 0.64 ± 0.22 L/kg; Adults: 0.74 ± 0.15 L/kg; widely to all tissues including CSF and ocular tissue</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 1% to 2%</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates 2 to 49 days of age: 2.4 hours</p>
<p style="text-indent:-2em;margin-left:4em;">Children 9 months to 12 years: 2.4 ± 0.7 hours</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: Mean: IV: 3.5 ± 0.9 hours; Oral: 4.8 ± 0.9 hours; CrCl &lt;25 mL/minute: 10.7 ± 5.7 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (80% to 99% as unchanged drug)</p></div>
<div class="block phksp drugH1Div" id="F51196094"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Clearance is decreased and half-life is prolonged.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F11390229"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Ganciclovir richet</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Ganciclovir</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Cymevir | Itagan</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Ai lin wei | Di du | Le fan</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Vitrasert</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Cymevene</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Cymevene</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Cymevene</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Ganciclovir</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Cymevene</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Cytovene | Ganciclovir</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Cymevene | Cymevene IV</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Cymevene</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  &lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17392728">
<a name="17392728"></a>Acosta EP, Brundage RC, King JR, et al. Ganciclovir population pharmacokinetics in neonates following intravenous administration of ganciclovir and oral administration of a liquid valganciclovir formulation. <i>Clin Pharmacol Ther</i>. 2007;81(6):867-872. doi:10.1038/sj.clpt.6100150<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ganciclovir-systemic-drug-information/abstract-text/17392728/pubmed" id="17392728" target="_blank">17392728</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.1">
<a name="AAP.1"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. <i>Red Book: 2021 Report of the Committee on Infectious Diseases</i>. 32nd ed. American Academy of Pediatrics; 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20232081">
<a name="20232081"></a>Amir J, Wolf DG, Levy I. Treatment of Symptomatic Congenital Cytomegalovirus Infection With Intravenous Ganciclovir Followed by Long-Term Oral Valganciclovir. <i>Eur J Pediatr.</i> 2010;169(9):1061-1067.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ganciclovir-systemic-drug-information/abstract-text/20232081/pubmed" id="20232081" target="_blank">20232081</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17640310">
<a name="17640310"></a>Asberg A, Humar A, Rollag H, et al; VICTOR Study Group. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. <i>Am J Transplant</i>. 2007;7(9):2106-2113. doi:10.1111/j.1600-6143.2007.01910.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ganciclovir-systemic-drug-information/abstract-text/17640310/pubmed" id="17640310" target="_blank">17640310</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Bergin S, Ferguson W, Corcoran S, et al. Symptomatic primary cytomegalovirus infection in a HIV-positive pregnant woman. <i>Int J STD AIDS</i>. 2014;25(14):1041-1043. doi:10.1177/0956462414528314<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ganciclovir-systemic-drug-information/abstract-text/24648317/pubmed" id="24648317" target="_blank">24648317</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bradley.1">
<a name="Bradley.1"></a>Bradley JS, Nelson JD, Barnett ED, et al, eds. <i>Nelson's Pediatric Microbial Therapy</i>. 27th ed. American Academy of Pediatrics; 2021.</div>
</li>
<li>
<div class="reference">
                  Brandy RC, Schleiss MR, Witte DP, Siddiqi TA, Fame PT. Placental transfer of ganciclovir in a woman with acquired immunodeficiency syndrome and cytomegalovirus disease. <i>Pediatr Infect Dis J.</i> 2002;21(8):796-797. doi:10.1097/00006454-200208000-00023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ganciclovir-systemic-drug-information/abstract-text/12233717/pubmed" id="12233717" target="_blank">12233717</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19738014">
<a name="19738014"></a>Caldés A, Colom H, Armendariz Y, et al. Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral valganciclovir administration in solid organ transplant patients infected with cytomegalovirus. <i>Antimicrob Agents Chemother</i>. 2009;53(11):4816-4824. doi:10.1128/AAC.00085-09<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ganciclovir-systemic-drug-information/abstract-text/19738014/pubmed" id="19738014" target="_blank">19738014</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33542372">
<a name="33542372"></a>Cheng YC, Kang EY, Hwang YS, Hsiao CH. Treatment of cytomegalovirus anterior segment infection with intravitreal injection of ganciclovir in adjunction with or without oral valganciclovir: a long-term results. <i>Sci Rep</i>. 2021;11(1):3105. doi:10.1038/s41598-021-82637-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ganciclovir-systemic-drug-information/abstract-text/33542372/pubmed" id="33542372" target="_blank">33542372</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27090644">
<a name="27090644"></a>Choopong P, Vivittaworn K, Konlakij D, Thoongsuwan S, Pituksung A, Tesavibul N. Treatment outcomes of reduced-dose intravitreal ganciclovir for cytomegalovirus retinitis. <i>BMC Infect Dis</i>. 2016;16:164. doi:10.1186/s12879-016-1490-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ganciclovir-systemic-drug-information/abstract-text/27090644/pubmed" id="27090644" target="_blank">27090644</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Cytovene-IV (ganciclovir sodium) [prescribing information]. Montgomery, AL: H2-Pharma, LLC; June 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29507070">
<a name="29507070"></a>Dong Q, Leroux S, Shi HY, et al. Pilot study of model-based dosage individualization of ganciclovir in neonates and young infants with congenital cytomegalovirus infection. <i>Antimicrob Agents Chemother</i>. 2018;62(5):e00075-18. doi: 10.1128/AAC.00075-18<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ganciclovir-systemic-drug-information/abstract-text/29507070/pubmed" id="29507070" target="_blank">29507070</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOO">
<a name="Expert.DOO"></a>Expert opinion. Senior Obesity Editorial Team: Jeffrey F. Barletta, PharmD, FCCM; Manjunath P. Pai, PharmD, FCP; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3017630">
<a name="3017630"></a>Fletcher C, Sawchuk R, Chinnock B, et al. Human Pharmacokinetics of the Antiviral Drug DHPG. <i>Clin Pharmacol Ther.</i> 1986;40(3):281-286.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ganciclovir-systemic-drug-information/abstract-text/3017630/pubmed" id="3017630" target="_blank">3017630</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Ganciclovir sodium [prescribing information]. Lake Zurich, IL: Fresenius Kabi; August 2020.</div>
</li>
<li>
<div class="reference">
                  Ganciclovir Sodium [prescribing information]. Schaumburg, IL: Sagent Pharmaceuticals; August 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9428565">
<a name="9428565"></a>Gando S, Kameue T, Nanzaki S, et al. Pharmacokinetics and Clearance of Ganciclovir During Continuous Hemodiafiltration. <i>Crit Care Med.</i> 1998;26(1):184-187.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ganciclovir-systemic-drug-information/abstract-text/9428565/pubmed" id="9428565" target="_blank">9428565</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8380242">
<a name="8380242"></a>Goodrich JM, Bowden RA, Fisher L, et al. Ganciclovir Prophylaxis to Prevent Cytomegalovirus Disease After Allogeneic Marrow Transplant. <i>Ann Intern Med.</i> 1993;118(3):173-178.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ganciclovir-systemic-drug-information/abstract-text/8380242/pubmed" id="8380242" target="_blank">8380242</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22801826">
<a name="22801826"></a>Gore DM, Gore SK, Visser L. Progressive outer retinal necrosis: outcomes in the intravitreal era. <i>Arch Ophthalmol</i>. 2012;130(6):700-706. doi:10.1001/archophthalmol.2011.2622<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ganciclovir-systemic-drug-information/abstract-text/22801826/pubmed" id="22801826" target="_blank">22801826</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2547191">
<a name="2547191"></a>Gudnason T, Belani KK, Balfour HH Jr. Ganciclovir Treatment of Cytomegalovirus Disease in Immunocompromised Children. <i>Pediatr Infect Dis J.</i> 1989;8(7):436-440.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ganciclovir-systemic-drug-information/abstract-text/2547191/pubmed" id="2547191" target="_blank">2547191</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19397464">
<a name="19397464"></a>Heintz BH, Matzke GR, Dager WE. Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis. <i>Pharmacotherapy.</i> 2009;29(5):562-577.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ganciclovir-systemic-drug-information/abstract-text/19397464/pubmed" id="19397464" target="_blank">19397464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33201745">
<a name="33201745"></a>Ho SA, Slavin M, Roberts JA, Yong M. Optimization of ganciclovir use in allogeneic hematopoietic cell transplant recipients - the role of therapeutic drug monitoring. <i>Expert Rev Anti Infect Ther</i>. 2021;19(6):707-718. doi:10.1080/14787210.2021.1851193<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ganciclovir-systemic-drug-information/abstract-text/33201745/pubmed" id="33201745" target="_blank">33201745</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24145543">
<a name="24145543"></a>Horvatits T, Kitzberger R, Drolz A, et al. Pharmacokinetics of ganciclovir during continuous venovenous hemodiafiltration in critically ill patients. <i>Antimicrob Agents Chemother</i>. 2014;58(1):94-101. doi:10.1128/AAC.00892-13<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ganciclovir-systemic-drug-information/abstract-text/24145543/pubmed" id="24145543" target="_blank">24145543</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25738669">
<a name="25738669"></a>Kimberlin DW, Jester PM, Sánchez PJ, et al. Valganciclovir for symptomatic congenital cytomegalovirus disease. <i>N Engl J Med</i>. 2015;372(10):933-943. doi:10.1056/NEJMoa1404599<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ganciclovir-systemic-drug-information/abstract-text/25738669/pubmed" id="25738669" target="_blank">25738669</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29596116">
<a name="29596116"></a>Kotton CN, Kumar D, Caliendo AM, et al. The Third International Consensus Guidelines on the management of cytomegalovirus in solid-organ transplantation. <i>Transplantation</i>. 2018;102(6):900-931. doi:10.1097/TP.0000000000002191<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ganciclovir-systemic-drug-information/abstract-text/29596116/pubmed" id="29596116" target="_blank">29596116</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23896556">
<a name="23896556"></a>Kotton CN, Kumar D, Caliendo AM, et al. Updated international consensus guidelines on the management of cytomegalovirus in solid organ transplantation. <i>Transplantation.</i> 2013;96(4):333-360.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ganciclovir-systemic-drug-information/abstract-text/23896556/pubmed" id="23896556" target="_blank">23896556</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31425489">
<a name="31425489"></a>Krens SD, Hodiamont CJ, Juffermans NP, Mathôt RAA, van Hest RM. Population pharmacokinetics of ganciclovir in critically ill patients. <i>Ther Drug Monit</i>. 2020;42(2):295-301. doi:10.1097/FTD.0000000000000689<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ganciclovir-systemic-drug-information/abstract-text/31425489/pubmed" id="31425489" target="_blank">31425489</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2854457">
<a name="2854457"></a>Lake KD, Fletcher CV, Love KR, et al. Ganciclovir pharmacokinetics during renal impairment. <i>Antimicrob Agents Chemother.</i> 1988;32(12):1899-1900. doi:10.1128/AAC.32.12.1899<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ganciclovir-systemic-drug-information/abstract-text/2854457/pubmed" id="2854457" target="_blank">2854457</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22491927">
<a name="22491927"></a>Lalezary M, Recchia FM, Kim SJ. Treatment of congenital cytomegalovirus retinitis with intravitreous ganciclovir. <i>Arch Ophthalmol</i>. 2012;130(4):525-527. doi:10.1001/archophthalmol.2011.1615<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ganciclovir-systemic-drug-information/abstract-text/22491927/pubmed" id="22491927" target="_blank">22491927</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32547394">
<a name="32547394"></a>Li L, Li X, Xia Y, et al. Recommendation of antimicrobial dosing optimization during continuous renal replacement therapy. <i>Front Pharmacol</i>. 2020;11:786. doi:10.3389/fphar.2020.00786<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ganciclovir-systemic-drug-information/abstract-text/32547394/pubmed" id="32547394" target="_blank">32547394</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30535363">
<a name="30535363"></a>Marsico C, Aban I, Kuo H, et al. Blood viral load in symptomatic congenital cytomegalovirus infection. <i>J Infect Dis</i>. 2019;219(9):1398-1406. doi:10.1093/infdis/jiy695<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ganciclovir-systemic-drug-information/abstract-text/30535363/pubmed" id="30535363" target="_blank">30535363</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Matthews T, Boehme R. Antiviral Activity and Mechanism of Action of Ganciclovir. <i>Rev Infect Dis.</i> 1988;10(suppl 3):490-494.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21075610">
<a name="21075610"></a>McGloughlin S, Roberts JA, O'Donoghue S, Martin J, Briscoe S, Lipman J. Ganciclovir pharmacokinetics and suggested dosing in continuous venovenous haemodiafiltration. <i>Int J Antimicrob Agents</i>. 2011;37(1):90-92. doi:10.1016/j.ijantimicag.2010.10.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ganciclovir-systemic-drug-information/abstract-text/21075610/pubmed" id="21075610" target="_blank">21075610</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1313549">
<a name="1313549"></a>Merigan TC, Renlund DG, Keay S, et al. A Controlled Trial of Ganciclovir to Prevent Cytomegalovirus Disease After Heart Transplantation. <i>N Engl J Med. </i>1992;326(18):1182-1186.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ganciclovir-systemic-drug-information/abstract-text/1313549/pubmed" id="1313549" target="_blank">1313549</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Miller BW, Howard TK, Goss JA, Mostello DJ, Holcomb WL Jr, Brennan DC. Renal transplantation one week after conception. <i>Transplantation</i>. 1995;60(11):1353-1354.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ganciclovir-systemic-drug-information/abstract-text/8525535/pubmed" id="8525535" target="_blank">8525535</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7547787">
<a name="7547787"></a>Morlet N, Young S, Naidoo D, Fong T, Coroneo MT. High dose intravitreal ganciclovir for CMV retinitis: a shelf life and cost comparison study. <i>Br J Ophthalmol</i>. 1995;79(8):753-755. doi:10.1136/bjo.79.8.753<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ganciclovir-systemic-drug-information/abstract-text/7547787/pubmed" id="7547787" target="_blank">7547787</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11981729">
<a name="11981729"></a>Mylonakis E, Kallas WM, Fishman JA. Combination antiviral therapy for ganciclovir-resistant cytomegalovirus infection in solid-organ transplant recipients. <i>Clin Infect Dis</i> 2002;34(10):1337-1341.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ganciclovir-systemic-drug-information/abstract-text/11981729/pubmed" id="11981729" target="_blank">11981729</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27755504">
<a name="27755504"></a>Nicastro E, Giovannozzi S, Stroppa P, et al. Effectiveness of preemptive therapy for cytomegalovirus disease in pediatric liver transplantation. <i>Transplantation</i>. 2017;101(4):804-810. doi:10.1097/TP.0000000000001531<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ganciclovir-systemic-drug-information/abstract-text/27755504/pubmed" id="27755504" target="_blank">27755504</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24853257">
<a name="24853257"></a>Nunez-Nunez M, Bellapart J, O'Donoghue S, et al. Variable ganciclovir concentrations in a critically ill patient receiving continuous renal replacement therapy and plasma exchange? <i>Int J Antimicrob Agents</i>. 2014;43(6):572-573. doi:10.1016/j.ijantimicag.2014.03.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ganciclovir-systemic-drug-information/abstract-text/24853257/pubmed" id="24853257" target="_blank">24853257</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Osterholm EA, Schleiss MR. Impact of breast milk-acquired cytomegalovirus infection in premature infants: pathogenesis, prevention, and clinical consequences? <i>Rev Med Virol</i>. 2020;30(6):1-11. doi:10.1002/rmv.2117<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ganciclovir-systemic-drug-information/abstract-text/32662174/pubmed" id="32662174" target="_blank">32662174</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26824942">
<a name="26824942"></a>Padullés A, Colom H, Bestard O, et al. Contribution of population pharmacokinetics to dose optimization of ganciclovir-valganciclovir in solid-organ transplant patients. <i>Antimicrob Agents Chemother</i>. 2016;60(4):1992-2002. doi:10.1128/AAC.02130-15<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ganciclovir-systemic-drug-information/abstract-text/26824942/pubmed" id="26824942" target="_blank">26824942</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Pescovitz MD. Absence of teratogenicity of oral ganciclovir used during early pregnancy in a liver transplant recipient. <i>Transplantation</i>. 1999;67(5):758-759. doi:10.1097/00007890-199903150-00021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ganciclovir-systemic-drug-information/abstract-text/10096536/pubmed" id="10096536" target="_blank">10096536</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Puliyanda DP, Silverman NS, Lehman D, et al. Successful use of oral ganciclovir for the treatment of intrauterine cytomegalovirus infection in a renal allograft recipient. <i>Transpl Infect Dis</i>. 2005;7(2):71-74. doi:10.1111/j.1399-3062.2005.00089.x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ganciclovir-systemic-drug-information/abstract-text/16150094/pubmed" id="16150094" target="_blank">16150094</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30817026">
<a name="30817026"></a>Razonable RR, Humar A. Cytomegalovirus in solid organ transplant recipients-Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice. <i>Clin Transplant</i>. 2019;33(9):e13512. doi:10.1111/ctr.13512<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ganciclovir-systemic-drug-information/abstract-text/30817026/pubmed" id="30817026" target="_blank">30817026</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21941226">
<a name="21941226"></a>Saitoh A, Sakamoto S, Fukuda A, et al. A universal preemptive therapy for cytomegalovirus infections in children after live-donor liver transplantation. <i>Transplantation</i>. 2011;92(8):930-935. doi:10.1097/TP.0b013e31822d873d<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ganciclovir-systemic-drug-information/abstract-text/21941226/pubmed" id="21941226" target="_blank">21941226</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15685150">
<a name="15685150"></a>Schleiss MR. Antiviral Therapy of Congenital Cytomegalovirus Infection. <i>Semin Pediatr Infect Dis.</i> 2005;16(1):50-59.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ganciclovir-systemic-drug-information/abstract-text/15685150/pubmed" id="15685150" target="_blank">15685150</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33515202">
<a name="33515202"></a>Selby PR, Shakib S, Peake SL, et al. A systematic review of the clinical pharmacokinetics, pharmacodynamics and toxicodynamics of ganciclovir/valganciclovir in allogeneic haematopoietic stem cell transplant patients. <i>Clin Pharmacokinet</i>. 2021;60(6):727-739. doi:10.1007/s40262-020-00982-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ganciclovir-systemic-drug-information/abstract-text/33515202/pubmed" id="33515202" target="_blank">33515202</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23042013">
<a name="23042013"></a>Singh R, Singh R, Trehan A, Jain R, Bhalekar S. Cytomegalovirus retinitis in an ALL child on exclusive chemotherapy treated successfully with intravitreal ganciclovir alone. <i>J Pediatr Hematol Oncol</i>. 2013;35(3):e118-e119. doi: 10.1097/MPH.0b013e31827078ad<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ganciclovir-systemic-drug-information/abstract-text/23042013/pubmed" id="23042013" target="_blank">23042013</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Society for Maternal-Fetal Medicine (SMFM), Hughes BL, Gyamfi-Bannerman C. Diagnosis and antenatal management of congenital cytomegalovirus infection. <i>Am J Obstet Gynecol.</i> 2016;214(6):B5-B11. doi:10.1016/j.ajog.2016.02.042<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ganciclovir-systemic-drug-information/abstract-text/26902990/pubmed" id="26902990" target="_blank">26902990</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Sommadossi JP, Bevan R, Ling T, et al. Clinical Pharmacokinetics of Ganciclovir in Patients With Normal and Impaired Renal Function. <i>Rev Infect Dis.</i> 1988;10(suppl 3):507-514.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25428442">
<a name="25428442"></a>Stockmann C, Roberts JK, Knackstedt ED, Spigarelli MG, Sherwin CM. Clinical pharmacokinetics and pharmacodynamics of ganciclovir and valganciclovir in children with cytomegalovirus infection. <i>Expert Opin Drug Metab Toxicol</i>. 2015;11(2):205-219. doi:10.1517/17425255.2015.988139<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ganciclovir-systemic-drug-information/abstract-text/25428442/pubmed" id="25428442" target="_blank">25428442</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26962197">
<a name="26962197"></a>Stockmann C, Sherwin CM, Knackstedt ED, Hersh AL, Pavia AT, Spigarelli MG. Therapeutic drug monitoring of ganciclovir treatment for cytomegalovirus infections among immunocompromised children. <i>J Pediatric Infect Dis Soc</i>. 2016;5(2):231-232. doi:10.1093/jpids/piw008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ganciclovir-systemic-drug-information/abstract-text/26962197/pubmed" id="26962197" target="_blank">26962197</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27565955">
<a name="27565955"></a>Suresh S, Lee BE, Robinson JL, Akinwumi MS, Preiksaitis JK. A risk-stratified approach to cytomegalovirus prevention in pediatric solid organ transplant recipients. <i>Pediatr Transplant</i>. 2016;20(7):970-980. doi:10.1111/petr.12786<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ganciclovir-systemic-drug-information/abstract-text/27565955/pubmed" id="27565955" target="_blank">27565955</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1846060">
<a name="1846060"></a>Swan SK, Munar MY, Wigger MA, Bennett WM. Pharmacokinetics of ganciclovir in a patient undergoing hemodialysis. <i>Am J Kidney Dis</i>. 1991;17(1):69-72. doi:10.1016/s0272-6386(12)80253-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ganciclovir-systemic-drug-information/abstract-text/1846060/pubmed" id="1846060" target="_blank">1846060</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15227610">
<a name="15227610"></a>Tice AD, Rehm SJ, Dalovisio JR, et al. Practice guidelines for outpatient parenteral antimicrobial therapy <i>Clin Infect Dis</i>. 2004;38(12):1651–1672.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ganciclovir-systemic-drug-information/abstract-text/15227610/pubmed" id="15227610" target="_blank">15227610</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19747629">
<a name="19747629"></a>Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. <i>Biol Blood Marrow Transplant </i>2009;15(10):1143-1238.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ganciclovir-systemic-drug-information/abstract-text/19747629/pubmed" id="19747629" target="_blank">19747629</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16163635">
<a name="16163635"></a>Trotman RL, Williamson JC, Shoemaker DM, et al. Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy. <i>Clin Infect Dis.</i> 2005;41(8):1159-1166.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ganciclovir-systemic-drug-information/abstract-text/16163635/pubmed" id="16163635" target="_blank">16163635</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18582201">
<a name="18582201"></a>Tunkel AR, Glaser CA, Bloch KC, et al. The Management of Encephalitis: Clinical Practice Guidelines from the Infectious Diseases Society of America. <i>Clin Infect Dis.</i> 2008;47(3):303-327.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ganciclovir-systemic-drug-information/abstract-text/18582201/pubmed" id="18582201" target="_blank">18582201</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services (HHS); Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed January 4, 2024.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.5">
<a name="HHS.5"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href="https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-oi/guidelines-adult-adolescent-oi.pdf" target="_blank">https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-oi/guidelines-adult-adolescent-oi.pdf</a>. Updated July 22, 2021. Accessed August 9, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.2">
<a name="HHS.2"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href="https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-oi/guidelines-adult-adolescent-oi.pdf" target="_blank">https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-oi/guidelines-adult-adolescent-oi.pdf</a>. Updated May 3, 2022. Accessed July 12, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.3">
<a name="HHS.3"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children. <a href="https://clinicalinfo.hiv.gov/en/guidelines/pediatric-opportunistic-infection/whats-new" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/pediatric-opportunistic-infection/whats-new</a>. Updated March 19, 2021. Accessed May 25, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.4">
<a name="HHS.4"></a>US Department of Health and Human Services (HHS) Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission. Recommendations for the use of antiretroviral drugs during pregnancy and interventions to reduce perinatal HIV transmission in the United States. <a href="https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Perinatal_GL.pdf" target="_blank">https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Perinatal_GL.pdf</a>. Updated December 30, 2021. Accessed January 3, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17430487">
<a name="17430487"></a>Vethamuthu J, Feber J, Chretien A, Lampe D, Filler G. Unexpectedly high inter- and intrapatient variability of ganciclovir levels in children. <i>Pediatr Transplant</i>. 2007;11(3):301-305. doi:10.1111/j.1399-3046.2006.00669.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ganciclovir-systemic-drug-information/abstract-text/17430487/pubmed" id="17430487" target="_blank">17430487</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9709750">
<a name="9709750"></a>Young S, Morlet N, Besen G, et al. High-dose (2000-microgram) intravitreous ganciclovir in the treatment of cytomegalovirus retinitis. <i>Ophthalmology</i>. 1998;105(8):1404-1410. doi:10.1016/s0161-6420(98)98020-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ganciclovir-systemic-drug-information/abstract-text/9709750/pubmed" id="9709750" target="_blank">9709750</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24252753">
<a name="24252753"></a>Zhang B, Fila M, Fakhoury M, et al. Pharmacokinetics and dosage individualization of ganciclovir and valganciclovir in an infant with nephrotic syndrome associated with cytomegalovirus infection. <i>J Antimicrob Chemother</i>. 2014;69(4):1150-1151. doi:10.1093/jac/dkt472<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ganciclovir-systemic-drug-information/abstract-text/24252753/pubmed" id="24252753" target="_blank">24252753</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9140 Version 298.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
